3^rd World Congress on Breast Cancer August 08-09, 2022 Toronto, Canada

Dr. Thakur's research activities are focused on 1) developing new and innovative therapeutic approaches to enhance clinical and anti-tumor immune responses; 2) developing novel strategies to attenuate the immune suppressive cellular and humoral factors.

Hematology and Oncology

Dr. Kanchan Kohli, M. Pharm, Ph.D (Pharmaceutics) is presently working as an Associate Professor in Dept. of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi, India with an overall 35 years of teaching experience in under graduation and post graduation courses and research experience

Plants have a milieu of phytochemicals that provides protection and treatment of chronic diseases. They are being extensively studied to evaluate their effects for the welfare of public. Much scientific research needs to be conducted before we can begin to make science-based recommendations and launch their formulations in market. Therefore, research is focused on development of novel drug delivery carriers of natural products for their bioavailability enhancement and targeted drug delivery. Other research area includes formulation of conventional dosage forms like tablets and cap

Prof.Nitin Telang obtained his PhD degree in Experimental Embryology in 1974 from the University of Poona, India. He immigrated to the USA in 1976, and obtained his post-doctoral training at the University of Nebraska, Lincoln, NE, American Health Foundation, Valhalla, NY and Sloan-Kettering Institute New York, NY (1976-1985). During his post-doctoral training, he conducted research on the initiation and progression of breast and colon carcinogenesis in organ cultures of target tissue. As a faculty member, Dr Telang served as Attending Biochemist, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY (1985-1991), and as Associate Professor, Department of Surgery, Weill-Cornell Medical College, New York, NY (1991-2004). His last academic appointment was as Senior Scientist, and Director, Carcinogenesis and Prevention Laboratory, Strang Cancer Prevention Center, New York, NY (2004-2007)

Research interest includes Endocrinology, Internal Medicine, Hormonal Therapy, Hormonal Disorders, Behavioral Endocrinology, and Cancer

Professor Wei Xu, Marian A. Messerschmidt Professor of Cancer Research Genetics Program Co-Leader , UW Carbone Cancer Center. Education BS, 1991, Chemistry, Beijing University, China MS, 1994, Biophysics, Institute of Biophysics, Beijing, China PhD, 1999, Biochemistry, University of Iowa Postdoctoral Research, The Salk Institute for Biological Studies, La Jolla, CA Honors and Awards Shaw Scientist Award, 2008 DOD ERA of HOPE Scholar, 2010 Society of Toxicology Achievement Award, 2013 Villas Distinguished Achievement Professor, University of Wisconsin, 2014 Romnes Faculty Fellowship, University of Wisconsin, 2016 Marian A. Messerschmidt Professorship, 2016 AACR-Bayer Innovation and Discovery Grant Awardee, 2019 Kellett Mid-Career Award, University of Wisconsin-Madison, 2019

Breast cancer prevention and treatment using environmental and nutritional estrogenic compounds. Mechanism of transcription activation of ERa and ERb by environmental estrogenic ligands.

Benny Abraham Kaipparettu major research interest of Dr. Kaipparettu is in breast cancer stem cells (His publications before 2006 was with the name Abraham BK due to official name change). After bachelor and master degree in pharmacy, Dr. Kaipparettu continued his career in pharmacogenomics and obtained PhD in Pharmacology for his research in CYP2D6 polymorphism. During his first postdoctoral fellowship in Germany, Dr. Kaipparettu focused on pharmacogenomics in breast cancer. In 2003 when initial reports about putative breast cancer stem cells (BCSCs) published, he investigated its clinical significance in breast tumors and published one of the first studies on the clinical significance of BCSCs. His observations suggested the relevance of BCSCs in distant metastasis. The findings in his publication were further verified by several other research groups and extensively cited in other cancer stem cell publications. Later he moved to Baylor College of Medicine, Houston, USA and continued his work on the regulation of cancer stem cell markers by hormone receptors and its epigenetic silencing. Mean time, he also focused on the higher order regulation of clustered genes by scaffold proteins and the development of economic technologies for three dimensional (3D) cell culture. In 2009 Dr Kaipparettu was promoted as a Junior Faculty in Baylor College of Medicine and in 2010 he has became an Assistant Professor in the Department of Molecular and Human Genetics, Baylor College of Medicine.

Tumour initiating cells, Mitochondrial Nuclear Cross talk in Cancer, Cancer epigenetics, Pharmacogenomics, Epigenetics and energy regulation in breast tumor initiating cells.

Portnoy Sergey Mikhailovich, 1968-1974 was studied at the Vladivostok Medical Institute and the 1st Leningrad Order of Lenin Medical Institute named after Academician I.P. Pavlov. 1974-1975 internship in surgery at the 1st Moscow Order of Lenin Medical Institute named after Academician I.M.Sechenov. 1975 - 2017 residency, postgraduate studies and work at the Federal State Budgetary Institution "Russian Cancer Research Center named after NN Blokhin "of the Ministry of Health of Russia (formerly the Institute of Experimental and Clinical Oncology of the RAMS of the USSR) as a junior researcher, researcher, senior researcher, leading researcher, head of the department (Surgical Department No. 8 of Operative Mammology). From 2017 to the present, I have been working in several private clinics in Moscow. Since 2021 I have been a consultant at BIMK-Cardio JSC.

Oncology